GlaxoSmithKline Revenue 2006-2019 | GSK
GlaxoSmithKline annual/quarterly revenue history and growth rate from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- GlaxoSmithKline revenue for the quarter ending September 30, 2019 was $11.573B, a 9.76% increase year-over-year.
- GlaxoSmithKline revenue for the twelve months ending September 30, 2019 was $38.252B, a 14.25% decline year-over-year.
- GlaxoSmithKline annual revenue for 2018 was $41.14B, a 5.75% increase from 2017.
- GlaxoSmithKline annual revenue for 2017 was $38.904B, a 2.93% increase from 2016.
- GlaxoSmithKline annual revenue for 2016 was $37.798B, a 3.33% increase from 2015.
GlaxoSmithKline Annual Revenue
(Millions of US $) |
| 2018 |
$41,140 |
| 2017 |
$38,904 |
| 2016 |
$37,798 |
| 2015 |
$36,578 |
| 2014 |
$37,916 |
| 2013 |
$41,475 |
| 2012 |
$41,896 |
| 2011 |
$43,940 |
| 2010 |
$43,903 |
| 2009 |
$44,421 |
| 2008 |
$45,173 |
| 2007 |
$45,455 |
| 2006 |
$42,804 |
| 2005 |
$39,443 |
GlaxoSmithKline Quarterly Revenue
(Millions of US $) |
| Q3 2019 |
$11,573 |
| Q2 2019 |
$10,040 |
| Q1 2019 |
$9,978 |
| Q4 2018 |
$6,661 |
| Q3 2018 |
$10,544 |
| Q2 2018 |
$9,949 |
| Q1 2018 |
$13,986 |
| Q4 2017 |
$10,128 |
| Q3 2017 |
$10,268 |
| Q2 2017 |
$9,361 |
| Q1 2017 |
$9,147 |
| Q4 2016 |
$9,595 |
| Q3 2016 |
$9,905 |
| Q2 2016 |
$9,373 |
| Q1 2016 |
$8,925 |
| Q4 2015 |
$9,617 |
| Q3 2015 |
$9,498 |
| Q2 2015 |
$9,020 |
| Q1 2015 |
$8,512 |
| Q4 2014 |
$9,319 |
| Q3 2014 |
$9,120 |
| Q2 2014 |
$9,472 |
| Q1 2014 |
$9,440 |
| Q4 2013 |
$11,235 |
| Q3 2013 |
$10,518 |
| Q2 2013 |
$10,166 |
| Q1 2013 |
$9,875 |
| Q4 2012 |
$10,782 |
| Q3 2012 |
$10,512 |
| Q2 2012 |
$10,210 |
| Q1 2012 |
$10,717 |
| Q4 2011 |
$10,990 |
| Q3 2011 |
$11,304 |
| Q2 2011 |
$10,950 |
| Q1 2011 |
$10,544 |
| Q4 2010 |
$11,636 |
| Q3 2010 |
$10,560 |
| Q2 2010 |
$9,196 |
| Q1 2010 |
$11,286 |
| Q4 2009 |
$13,218 |
| Q3 2009 |
$11,097 |
| Q2 2009 |
$10,527 |
| Q1 2009 |
$9,734 |
| Q4 2008 |
$10,522 |
| Q3 2008 |
$11,158 |
| Q2 2008 |
$11,689 |
| Q1 2008 |
$11,247 |
| Q4 2007 |
$12,116 |
| Q3 2007 |
$11,067 |
| Q2 2007 |
$11,263 |
| Q1 2007 |
$10,927 |
| Q4 2006 |
$11,417 |
| Q3 2006 |
$10,645 |
| Q2 2006 |
$10,696 |
| Q1 2006 |
$10,198 |
| Q4 2005 |
$10,363 |
| Q3 2005 |
$9,770 |
| Q2 2005 |
$9,538 |
| Q1 2005 |
$9,561 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$119.448B |
$41.140B |
|
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
|
